Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to "Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations" [Eur J Cancer 207 (2024) 114158].
Kron A, Scheffler M, Wiesweg M, Hummel HD, Kulhavy J, Gatteloehner S, Kollmeier J, Schubart C, Groß T, Demes MC, Keymel S, Joosten M, Merkelbach-Bruse S, Woelwer CB, Tufman A, Kauffmann-Guerrero D, Oeser K, Zehaczek M, Jeratsch U, Wolf J. Kron A, et al. Among authors: jeratsch u. Eur J Cancer. 2024 Oct 29;213:115074. doi: 10.1016/j.ejca.2024.115074. Online ahead of print. Eur J Cancer. 2024. PMID: 39476444 Free article. No abstract available.
Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations.
Kron A, Scheffler M, Wiesweg M, Hummel HD, Kulhavy J, Gatteloehner S, Kollmeier J, Schubart C, Groß T, Demes MC, Keymel S, Joosten M, Merkelbach-Bruse S, Wölwer CB, Tufman A, Kauffmann-Guerrero D, Oeser K, Zehaczek M, Jeratsch U, Wolf J. Kron A, et al. Among authors: jeratsch u. Eur J Cancer. 2024 Aug;207:114158. doi: 10.1016/j.ejca.2024.114158. Epub 2024 Jun 14. Eur J Cancer. 2024. PMID: 38941869 Free article.
Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
V Stackelberg A, Jäschke K, Jousseaume E, Templin C, Jeratsch U, Kosmides D, Steffen I, Gökbuget N, Peters C. V Stackelberg A, et al. Among authors: jeratsch u. Leukemia. 2023 Dec;37(12):2346-2355. doi: 10.1038/s41375-023-02042-4. Epub 2023 Oct 25. Leukemia. 2023. PMID: 37880478 Free PMC article.
Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer.
Lux MP, Böhme S, Hücherig S, Jeratsch U, Kürschner N, Lüftner D. Lux MP, et al. Among authors: jeratsch u. Breast Cancer Res Treat. 2019 Aug;176(3):495-506. doi: 10.1007/s10549-019-05262-4. Epub 2019 May 7. Breast Cancer Res Treat. 2019. PMID: 31065873 Free PMC article. Review.
Metabolite profiling reveals new insights into the regulation of serum urate in humans.
Albrecht E, Waldenberger M, Krumsiek J, Evans AM, Jeratsch U, Breier M, Adamski J, Koenig W, Zeilinger S, Fuchs C, Klopp N, Theis FJ, Wichmann HE, Suhre K, Illig T, Strauch K, Peters A, Gieger C, Kastenmüller G, Doering A, Meisinger C. Albrecht E, et al. Among authors: jeratsch u. Metabolomics. 2014;10(1):141-151. doi: 10.1007/s11306-013-0565-2. Epub 2013 Jul 20. Metabolomics. 2014. PMID: 24482632 Free PMC article.